In this evaluation, two geographically separated cohorts of CRC patients with metastatic disease from Germany and Australia were selected to represent the intended use population for anti-EGFR therapy, with plasma taken at the time of tissue biopsy or surgical resection. Here, EGFR is linked to colorectal carcinoma.